Press Releases



 
Press Releases
  Date Title View
Mar 29, 2017
REDWOOD CITY, Calif., March 29, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of new results from a large multi-center validation study, which confirmed that the Oncotype DX® Genomic Prostate Score™ (GPS) is a strong independent predictor of metastases at 10 years in prostate cancer patients ac...
PDF
Mar 24, 2017
REDWOOD CITY, Calif., March 24, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry in the peer-reviewed journal Breast Cancer Research and Treatment, reconfirming the value of the Oncotype DX Breast...
PDF
Mar 20, 2017
REDWOOD CITY, Calif., March 20, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from 15 Oncotype DX Breast Recurrence Score® studies conducted in 12 countries that provide real-world evidence of the test's ability to change treatment decisions in breast cancer patients. The new findings, presented at the 15th S...
PDF
Feb 28, 2017
REDWOOD CITY, Calif., Feb. 28, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at the Cowen and Company 37th Annual Health Care Conference at the Marriot Copley Place in Boston on Tuesday, March 7, 2017 at 11:20 a.m. Eastern Time. ...
PDF
Feb 16, 2017
REDWOOD CITY, Calif., Feb. 16, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) announced today the presentation of results from four studies evaluating the clinical value and utility of its Oncotype DX® Genomic Prostate Score™ (GPS) in the management of early-stage prostate cancer. Collectively, these new data highlight the test...
PDF
Feb 14, 2017
REDWOOD CITY, Calif., Feb. 14, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2016. Total revenue was $327.9 million in the full year 2016, compared with $287.5 million in 2015, an increase of 14 percent. U.S. product revenue ...
PDF
Feb 7, 2017
REDWOOD CITY, Calif., Feb. 7, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, February 14 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2016 financial results.  The call and webcast will follow the release of the fourth quarter and y...
PDF
Jan 3, 2017
REDWOOD CITY, Calif., Jan. 3, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at the 35th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Monday, January 9, 2017 at 11:00 a.m. Pacific Ti...
PDF
Dec 22, 2016
REDWOOD CITY, Calif., Dec. 22, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that based on unparalleled clinical evidence, the American Joint Committee on Cancer (AJCC) incorporated the Oncotype DX® test in its recently published Eighth Edition AJCC Cancer Staging Manual. Representing a rigorous, multi-disciplinary a...
PDF
Dec 9, 2016
REDWOOD CITY, Calif., Dec. 9, 2016 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple studies demonstrating the unparalleled value of the Oncotype DX® test in individualizing breast cancer treatment decisions for patients with various stages of the disease. Presentations included two overviews of prospect...
PDF
FirstPrevious
3
...
NextLast